Rob Goldstein will be online to answer all of your questions on the latest ALS research and developments.
The Food and Drug Administration announced today it has granted approval to MT Pharma America to begin marketing edaravone as a treatment for amyotrophic lateral sclerosis (ALS). The approval of edaravone marks the first new treatment to be approved for ALS in the United States since Rilutek® (Riluzole) was approved in 1995. This webinar will discuss what this important announcement means for people living with ALS today.
Join Gleneagles Country Club and receve a portion off your initiation when you donate to Charity Classic.
Contact our Membership Department for more information. 972.867.6666 x202.
tennis tournament and auction